-

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Scientific™ KingFisher™ PlasmidPro prepares high purity plasmid DNA in approximately 75 minutes, half the traditional process time and without the need for centrifugation

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ KingFisher™ PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention. This is the latest addition to the Thermo Scientific KingFisher instrument portfolio which offers a wide range of plasmid DNA extraction products to help drive efficiency and consistency.

Globally, there are approximately 1,700 clinical trials for cell and gene therapies.1 In recent years, plasmids have been instrumental in the development of cell and gene therapies, monoclonal antibody therapies and mRNA therapies and vaccines. Plasmids are commonly used in a variety of molecular biology applications, including transfection, protein expression, gene therapy, DNA sequencing, and vaccine development. They are a critical laboratory tool that can act as a carrier to deliver desired genes or DNA fragments into target cells.

“With the rapidly growing demand for plasmid DNA purification for emerging therapies, we are proud to accelerate the purification process with a ‘press and go’ solution,” said Amy Butler, president, biosciences, Thermo Fisher Scientific. “By fully automating a critical step in plasmid DNA manufacturing, the PlasmidPro DNA purification system can give time back to our customers to focus on their research and bringing life-saving therapies and vaccines to patients.”

The PlasmidPro purification system requires no set-up, centrifugation or pipetting and completely automates the purification process from culture to plasmid. The product uses a self-contained cartridge pre-filled with all necessary reagents to perform the purification, eliminating the need for additional instrumentation and plastics while minimizing set-up time and contamination risks. Using 100-150 mL of fresh overnight culture, the system is capable of producing up to 1.5 mg DNA yield.

For more information on PlasmidPro, please visit thermofisher.com/plasmidpro.

*For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

1 https://alliancerm.org/wp-content/uploads/2024/05/Trials_Final_Q1_2024.pdf

Contacts

Media Contact Information:
Name: Kristin Blake
Phone: 760-637-1166
E-mail: kristin.blake@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Name: Kristin Blake
Phone: 760-637-1166
E-mail: kristin.blake@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.78...

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earning...

Nalgene Outdoor Unveils Thrill & Motion: A High-Energy Color Collection for 2026

ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces Thrill & Motion, a dynamic new collection crafted for people who embrace an active, on-the-go lifestyle; whether exploring trails, chasing waves, or simply navigating everyday life. For more than 75 years, Nalgene has set the standard in durable, reusable bottles. And since pioneering the use of bold color design in the category in the early ’90s, the brand continues to lead with palettes that spark individuality and adventu...
Back to Newsroom